Visual Abstract

Visual Abstract Big
Visual Abstract Big
View largeDownload slide
Visual Abstract Big
Visual Abstract Big
View largeDownload slide
Keywords:
Bicarbonate, Dietary alkali, Metabolic acidosis, Health outcomes, Acid, Alkali, Cardiovascular disease risk, Chronic kidney disease, Chronic metabolic acidosis, Diet

Background: Current guidelines recommend treatment of metabolic acidosis in chronic kidney disease (CKD) with sodium-based alkali. We tested the hypothesis that treatment with base-producing fruits and vegetables (F + V) better improves cardiovascular disease (CVD) risk indicators than oral sodium bicarbonate (NaHCO3). Methods: We randomized 108 macroalbuminuric, matched, nondiabetic CKD patients with metabolic acidosis to F + V (n = 36) in amounts to reduce dietary acid by half, oral NaHCO3 (HCO3, n = 36) 0.3 mEq/kg bw/day, or to Usual Care (UC, n = 36) to assess the 5-year effect of these interventions on estimated glomerular filtration rate (eGFR) course as the primary analysis and on indicators of CVD risk as the secondary analysis. Results: Five-year plasma total CO2 was higher in HCO3 and F + V than UC but was not different between HCO3 and F + V (difference p value < 0.01). Five-year net eGFR decrease was less in HCO3 (mean –12.3, 95% CI –12.9 to –11.7 mL/min/1.73 m2) and F + V (–10.0, 95% CI –10.6 to –9.4 mL/min/1.73 m2) than UC (–18.8, 95% CI –19.5 to –18.2 mL/min/1.73 m2; p value < 0.01) but was not different between HCO3 and F + V. Five-year systolic blood pressure was lower in F + V than UC and HCO3 (p value < 0.01). Despite similar baseline values, F + V had lower low-density lipoprotein, Lp(a), and higher serum vitamin K1 (low serum K1 is associated with coronary artery calcification) than HCO3 and UC at 5 years. Conclusion: Metabolic acidosis improvement and eGFR preservation were comparable in CKD patients treated with F + V or oral NaHCO3 but F + V better improved CVD risk indicators, making it a potentially better treatment option for reducing CVD risk.

Keywords:
Bicarbonate, Dietary alkali, Metabolic acidosis, Health outcomes, Acid, Alkali, Cardiovascular disease risk, Chronic kidney disease, Chronic metabolic acidosis, Diet
1.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.
Arch Intern Med
. 2004 Mar; 164(6): 659–63.
2.
US Renal Data System.
USRDS 2016 Annual Data Report
. Bethesda (MD): The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017.
3.
Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction.
Am Heart J
. 2012 Mar; 163(3): 399–406.
4.
Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis.
Nephrol Dial Transplant
. 2015 Jul; 30(7): 1162–9.
5.
Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD.
Nephrol Dial Transplant
. 2009 Apr; 24(4): 1232–7.
6.
Clase CM, Kiberd BA, Garg AX. Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III).
Nephron Clin Pract
. 2007; 105(4):c178–84.
7.
Remer T. Influence of nutrition on acid-base balance—metabolic aspects.
Eur J Nutr
. 2001 Oct; 40(5): 214–20.
8.
Adeva MM, Souto G. Diet-induced metabolic acidosis.
Clin Nutr
. 2011 Aug; 30(4): 416–21.
9.
Guidelines KD. Chapter 3: Management of progression and complications of CKD. Kidney Int Suppl (2011). 2013 Jan; 3(1): 73–90.
10.
Moore LV, Thompson FE. Adults Meeting Fruit and Vegetable Intake Recommendations - United States, 2013. MMWR Morb Mortal Wkly Rep. 2015 Jul; 64: 709–13.
11.
Fernandes AS, Ramos CK, Nerbass FB, Cuppari L. Diet quality of chronic kidney disease patients and the impact of nutritional counseling.
J Ren Nutr
. 2018 Nov; 28(6): 403–10.
12.
Goraya N, Simoni J, Jo CH, Wesson DE. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate.
Clin J Am Soc Nephrol
. 2013 Mar; 8(3): 371–81.
13.
Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.
Kidney Int
. 2014 Nov; 86: 1031–8.
14.
Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies.
BMJ
. 2014 Jul; 349:g4490.
15.
Gutiérrez OM, Muntner P, Rizk DV, McClellan WM, Warnock DG, Newby PK, et al. Dietary patterns and risk of death and progression to ESRD in individuals with CKD: a cohort study.
Am J Kidney Dis
. 2014 Aug; 64(2): 204–13.
16.
Smyth A, Griffin M, Yusuf S, Mann JF, Reddan D, Canavan M, et al. Diet and major renal outcomes: A prospective cohort study. The NIH-AARP Diet and health study.
J Ren Nutr
. 2016 Sep; 26(5): 288–98.
17.
Djoussé L, Arnett DK, Coon H, Province MA, Moore LL, Ellison RC. Fruit and vegetable consumption and LDL cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study.
Am J Clin Nutr
. 2004 Feb; 79(2): 213–7.
18.
Storey BC, Staplin N, Haynes R, Reith C, Emberson J, Herrington WG, et al.; SHARP Collaborative Group. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Kidney Int
. 2018 Apr; 93(4): 1000–7.
19.
Miedema MD, Petrone A, Shikany JM, Greenland P, Lewis CE, Pletcher MJ, et al. Association of fruit and vegetable consumption during early adulthood with the prevalence of coronary artery calcium after 20 years of follow-up: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Circulation
. 2015 Nov; 132(21): 1990–8.
20.
Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, et al.; Society of Cardiovascular Computed Tomography. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography).
Circulation
. 2007 Jan; 115(3): 402–26.
21.
Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, et al.; CRIC Study Investigators. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study.
Am J Kidney Dis
. 2011 Oct; 58(4): 519–26.
22.
Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al.; CRIC Investigators. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease.
JAMA Cardiol
. 2017 Jun; 2(6): 635–43.
23.
Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix Gla protein.
Nephrology (Carlton)
. 2006 Oct; 11(5): 455–61.
24.
Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, et al. Vitamin K intake and status are low in hemodialysis patients.
Kidney Int
. 2012 Sep; 82(5): 605–10.
25.
National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure.
Am J Kidney Dis
. 2000 Jun; 35(6 Suppl 2):S1–140.
26.
Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.
Kidney Int
. 2010 Apr; 77(7): 617–23.
27.
Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.
Kidney Int
. 2010 Aug; 78(3): 303–9.
28.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al.; Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease.
N Engl J Med
. 1994 Mar; 330(13): 877–84.
29.
Wesson DE. Dietary HCO3 reduces distal tubule acidification by increasing cellular HCO3 secretion.
Am J Physiol
. 1996 Jul; 271(1 Pt 2):F132–42.
30.
Warmoth L, Regalado MM, Simoni J, Harrist RB, Wesson DE. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension.
Am J Med Sci
. 2005; 330: 111–9.
31.
Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension.
Am J Kidney Dis
. 2000 Apr; 35(4): 687–94.
32.
Roehm B, Simoni J, Prusynski J, Wesson DE. Cigarette smoking Attenuates kidney protection by angiotensin converting enzyme inhibition in nondiabetic CKD.
Am J Nephrol
. 2017; 46(4): 260–7.
33.
Goraya N, Simoni J, Jo CH, Wesson DE. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy.
Kidney Int
. 2012 Jan; 81(1): 86–93.
34.
Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH.
J Am Diet Assoc
. 1995 Jul; 95(7): 791–7.
35.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
JAMA
. 2003 May; 289(19): 2560–72.
36.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JAMA
. 2001 May; 285(19): 2486–97.
37.
Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System.
Scand J Clin Lab Invest
. 1999 Feb; 59(1): 1–8.
38.
Breslow, NE, Day NE. Statistical methods in Cancer Research. Volume I -The analysis of case-control studies. 1980. Who. International Agency for Research Cancer scientific publication No. 32.
39.
Sainani K. The importance of accounting for correlated observations.
PM R
. 2010 Sep; 2(9): 858–61.
40.
R version 3.5.0 (2018-04-23) – "Joy in Playing". Copyright © 2018 The R Foundation for Statistical Computing, Platform: x86_64-w64-mingw32/x64 (64-bit).
41.
Touloumis A. R Package multgee: A Generalized Estimating Equations Solver for Multinomial Responses.
J Stat Softw
. 2015; 64(8): 1–14.
42.
Pinheiro J, Bates D. DebRoy S, Sarkar D, R Core Team (2018). Nlme: Linear and Nonlinear Mixed Effects Models. R Package version 3.1-137, URL: https://CRAN.R-project.org/package=nlme.
43.
Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race.
J Am Soc Nephrol
. 2007 Jan; 18(1): 293–303.
44.
PASS 16 Power Analysis and Sample Size Software (2018), NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass.
45.
Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.
JAMA
. 2005 Apr; 293(14): 1737–45.
46.
Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.
Lancet Diabetes Endocrinol
. 2016 Oct; 4(10): 829–39.
47.
Chen Z, Qureshi AR, Parini P, Hurt-Camejo E, Ripsweden J, Brismar TB, et al. Does statins promote vascular calcification in chronic kidney disease?
Eur J Clin Invest
. 2017 Feb; 47(2): 137–48.
48.
Lin J, Khetarpal SA, Terembula K, Reilly MP, Wilson FP: Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study.
BMC Nephrol
2015 Aug; 16: 130.
49.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
N Engl J Med
. 2004 Sep; 351(13): 1296–305.
50.
de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status.
J Am Soc Nephrol
. 2009 Sep; 20(9): 2075–84.
51.
Garneata L, Stancu A, Dragomir D, Stefan G, Mircescu G. Ketoanalogue-supplemented vegetarian very low-protein diet and CKD progression.
J Am Soc Nephrol
. 2016 Jul; 27(7): 2164–76.
52.
Bundy JD, Chen J, Yang W, Budoff M, Go AS, Grunwald JE, et al.; CRIC Study Investigators. Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: the CRIC study.
Atherosclerosis
. 2018 Apr; 271: 53–60.
53.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
Eur Heart J
. 2012 Jul; 33(13): 1635–701.
54.
Raphael KL, Zhang Y, Ying J, Greene T. Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease.
Nephrology (Carlton)
. 2014 Oct; 19(10): 648–54.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.